Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma - PubMed
5 hours ago
- #immunotherapy
- #personalized neoantigen vaccination
- #hepatocellular carcinoma
- Sequential personalized neoantigen vaccination after first-line treatments shows safety and efficacy in advanced hepatocellular carcinoma (HCC).
- The clinical trial (ChiCTR2300067818) evaluated vaccination following TACE plus TKI/PD-1-based therapy in advanced HCC patients.
- Personalized neoantigens were identified via whole-exome and transcriptome sequencing, synthesized as long peptides, and administered subcutaneously with dual adjuvants.
- Out of 10 enrolled patients, 4 received vaccination, with 2 completing the full 8-injection regimen.
- The vaccination demonstrated excellent safety, with only mild injection-site reactions observed.
- Both patients who completed the regimen achieved partial response, with robust neoantigen-specific immune responses confirmed via Interferon-gamma ELISpot assays.
- Serum biomarkers (alpha-fetoprotein and Des-gamma-carboxy prothrombin) declined significantly during vaccination, correlating with clinical responses.
- The study supports further investigation of sequential neoantigen vaccination in larger clinical trials for advanced HCC.